Analysis of DNA hypermethylation in pancreatic cancer using methylation-specific PCR and bisulfite sequencing

13Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor and the fourth common cause of cancer death in the Western world. The lack of effective therapeutic strategies is attributed to the late diagnosis of this disease. Methylation markers could improve early detection and help in the surveillance of PDAC after treatment. Analysis of hypermethylation in the tumor tissue and tumor-derived exosomes might help to identify new therapeutic strategies and aid in the understanding of the pathophysiological changes occurring in pancreatic cancer. There are several methods for the detection of methylation events. Whereas methylation-specific PCR (MSP-PCR) is the method of choice, the cost reductions in DNA sequencing enables researchers to add bisulfite sequencing (BSS) to their repertoire if a small number of genes will be tested in a larger set of patients’ samples. During the last years, several techniques to isolate and analyze DNA methylation have been proposed, but DNA modification using sodium bisulfite is still the gold standard.

Cite

CITATION STYLE

APA

Liu, B., & Pilarsky, C. (2018). Analysis of DNA hypermethylation in pancreatic cancer using methylation-specific PCR and bisulfite sequencing. In Methods in Molecular Biology (Vol. 1856, pp. 269–282). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8751-1_16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free